Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats

Nasruddin E. El-Reyani, Ömer Bozdogan, I. Baczkó, I. Leprán, J. Papp

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, was investigated on the development of reperfusion-induced arrhythmias and it was compared to their blood glucose lowering action. Arrhythmias were produced by reperfusion following 6 min coronary artery ligation in anaesthetised rats. Glimepiride pretreatment (0.001-0.01-0.1-5.0 mg/kg i.p., 30 min before coronary occlusion) significantly decreased the incidence of irreversible ventricular fibrillation and increased the survival rate during reperfusion (64%, 61%, 60%, and 67% vs. 27% in controls). Glibenclamide produced similar effect (81% survival) only in a dose of 5 mg/kg, while smaller doses were ineffective. The minimal hypoglycaemic dose and the dose required to inhibit significantly the oral glucose loading-induced hyperglycaemia were similar (1 and 0.1 mg/kg, respectively) after glibenclamide and glimepiride. It is concluded that although the blood glucose lowering potency of glibenclamide and glimepiride is rather similar, glimepiride appears to be more potent than glibenclamide in preventing reperfusion-induced cardiac arrhythmias. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalEuropean Journal of Pharmacology
Volume365
Issue number2-3
DOIs
Publication statusPublished - Jan 22 1999

Fingerprint

glimepiride
Glyburide
Reperfusion
Cardiac Arrhythmias
Hypoglycemic Agents
Blood Glucose
Coronary Occlusion
Ventricular Fibrillation
Hyperglycemia
Ligation
Coronary Vessels
Glucose
Incidence

Keywords

  • Glibenclamide
  • Glimepiride
  • Rat, anaesthetized
  • Reperfusion arrhythmia

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. / El-Reyani, Nasruddin E.; Bozdogan, Ömer; Baczkó, I.; Leprán, I.; Papp, J.

In: European Journal of Pharmacology, Vol. 365, No. 2-3, 22.01.1999, p. 187-192.

Research output: Contribution to journalArticle

@article{1b4ca608d1b34b4a9829fd7d6796c72e,
title = "Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats",
abstract = "The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, was investigated on the development of reperfusion-induced arrhythmias and it was compared to their blood glucose lowering action. Arrhythmias were produced by reperfusion following 6 min coronary artery ligation in anaesthetised rats. Glimepiride pretreatment (0.001-0.01-0.1-5.0 mg/kg i.p., 30 min before coronary occlusion) significantly decreased the incidence of irreversible ventricular fibrillation and increased the survival rate during reperfusion (64{\%}, 61{\%}, 60{\%}, and 67{\%} vs. 27{\%} in controls). Glibenclamide produced similar effect (81{\%} survival) only in a dose of 5 mg/kg, while smaller doses were ineffective. The minimal hypoglycaemic dose and the dose required to inhibit significantly the oral glucose loading-induced hyperglycaemia were similar (1 and 0.1 mg/kg, respectively) after glibenclamide and glimepiride. It is concluded that although the blood glucose lowering potency of glibenclamide and glimepiride is rather similar, glimepiride appears to be more potent than glibenclamide in preventing reperfusion-induced cardiac arrhythmias. Copyright (C) 1999 Elsevier Science B.V.",
keywords = "Glibenclamide, Glimepiride, Rat, anaesthetized, Reperfusion arrhythmia",
author = "El-Reyani, {Nasruddin E.} and {\"O}mer Bozdogan and I. Baczk{\'o} and I. Lepr{\'a}n and J. Papp",
year = "1999",
month = "1",
day = "22",
doi = "10.1016/S0014-2999(98)00866-8",
language = "English",
volume = "365",
pages = "187--192",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats

AU - El-Reyani, Nasruddin E.

AU - Bozdogan, Ömer

AU - Baczkó, I.

AU - Leprán, I.

AU - Papp, J.

PY - 1999/1/22

Y1 - 1999/1/22

N2 - The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, was investigated on the development of reperfusion-induced arrhythmias and it was compared to their blood glucose lowering action. Arrhythmias were produced by reperfusion following 6 min coronary artery ligation in anaesthetised rats. Glimepiride pretreatment (0.001-0.01-0.1-5.0 mg/kg i.p., 30 min before coronary occlusion) significantly decreased the incidence of irreversible ventricular fibrillation and increased the survival rate during reperfusion (64%, 61%, 60%, and 67% vs. 27% in controls). Glibenclamide produced similar effect (81% survival) only in a dose of 5 mg/kg, while smaller doses were ineffective. The minimal hypoglycaemic dose and the dose required to inhibit significantly the oral glucose loading-induced hyperglycaemia were similar (1 and 0.1 mg/kg, respectively) after glibenclamide and glimepiride. It is concluded that although the blood glucose lowering potency of glibenclamide and glimepiride is rather similar, glimepiride appears to be more potent than glibenclamide in preventing reperfusion-induced cardiac arrhythmias. Copyright (C) 1999 Elsevier Science B.V.

AB - The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, was investigated on the development of reperfusion-induced arrhythmias and it was compared to their blood glucose lowering action. Arrhythmias were produced by reperfusion following 6 min coronary artery ligation in anaesthetised rats. Glimepiride pretreatment (0.001-0.01-0.1-5.0 mg/kg i.p., 30 min before coronary occlusion) significantly decreased the incidence of irreversible ventricular fibrillation and increased the survival rate during reperfusion (64%, 61%, 60%, and 67% vs. 27% in controls). Glibenclamide produced similar effect (81% survival) only in a dose of 5 mg/kg, while smaller doses were ineffective. The minimal hypoglycaemic dose and the dose required to inhibit significantly the oral glucose loading-induced hyperglycaemia were similar (1 and 0.1 mg/kg, respectively) after glibenclamide and glimepiride. It is concluded that although the blood glucose lowering potency of glibenclamide and glimepiride is rather similar, glimepiride appears to be more potent than glibenclamide in preventing reperfusion-induced cardiac arrhythmias. Copyright (C) 1999 Elsevier Science B.V.

KW - Glibenclamide

KW - Glimepiride

KW - Rat, anaesthetized

KW - Reperfusion arrhythmia

UR - http://www.scopus.com/inward/record.url?scp=0032933609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032933609&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(98)00866-8

DO - 10.1016/S0014-2999(98)00866-8

M3 - Article

C2 - 9988102

AN - SCOPUS:0032933609

VL - 365

SP - 187

EP - 192

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -